financetom
Business
financetom
/
Business
/
News Corp. Fiscal Q3 Adjusted EPS Increases, Revenue Falls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
News Corp. Fiscal Q3 Adjusted EPS Increases, Revenue Falls
May 8, 2024 2:13 PM

04:48 PM EDT, 05/08/2024 (MT Newswires) -- News Corp. ( NWSA ) reported fiscal Q3 adjusted earnings late Wednesday of $0.11 per diluted share, up from $0.09 a year earlier.

Two analysts polled by Capital IQ expected $0.13.

Revenue for the quarter ended March 31 was $2.42 billion, down from $2.45 billion a year earlier.

Analysts surveyed by Capital IQ expected $2.45 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
JetBlue Launches Senior Notes Offering, Term Loan
JetBlue Launches Senior Notes Offering, Term Loan
Aug 12, 2024
07:42 AM EDT, 08/12/2024 (MT Newswires) -- JetBlue Airways ( JBLU ) said Monday that it plans to offer $400 million of convertible senior notes due 2029. The carrier expects to grant initial purchasers a 13-day option to buy up to an additional $60 million of the notes. Net proceeds are expected to be used to repurchase a portion of...
Bitdeer Technologies Group's Q2 Loss Narrows, Revenue Rises
Bitdeer Technologies Group's Q2 Loss Narrows, Revenue Rises
Aug 12, 2024
07:36 AM EDT, 08/12/2024 (MT Newswires) -- Bitdeer Technologies Group ( BTDR ) reported a Q2 loss Monday of $0.14 per diluted share, narrower than its loss of $0.36 a year earlier. Analysts polled by Capital IQ expected earnings of $0.01. Revenue for the quarter ended June 30 was $99.2 million, compared with $93.8 million a year earlier. Analysts surveyed...
Ascendis Pharma Gets US FDA Approval of Hypoparathyroidism Therapy
Ascendis Pharma Gets US FDA Approval of Hypoparathyroidism Therapy
Aug 12, 2024
07:34 AM EDT, 08/12/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday the US Food and Drug Administration has approved Yorvipath, the company's treatment for hypoparathyroidism, a rare endocrine disease, in adults. The approval is based on data from the global phase 2 and 3 trials. The company said it is finalizing the manufacturing of a commercial product...
Top Premarket Gainers
Top Premarket Gainers
Aug 12, 2024
07:39 AM EDT, 08/12/2024 (MT Newswires) -- PS International ( PSIG ) shares surged 80% pre-bell Monday, extending Friday's rally. Veritone ( VERI ) advanced 18%, rebounding from Friday's slide. Nuburu ( BURU ) shares increased 7.3%, shaving losses from the previous session. Price: 3.6000, Change: +0.19, Percent Change: +5.57 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved